Parameter
| Biomarker | RUNX1-RUNX1T1/CBFβ-MYH11 | Full name | RUNX1-RUNX1 Translocation Partner 1/Core Binding Factor Beta-Myosin Heavy Chain 11 fusion gene | Molecular Type | Nucleic acid (DNA) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, prognosis | ||
| Disease | Acute Myeloid Leukemia (AML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Whole blood/bone marrow (FISH, RT-qPCR) | ||
| Pathobiological Mechanisms | t(8;21) or inv(16) generates fusion proteins, suppresses hematopoietic gene transcription, and blocks cell differentiation. | ||||
| Clinical Availability Status | Clinical validation/guideline recommendation: ELN guideline for favorable prognosis group indicators. | ||||
| Notes and Dynamics | Monotherapy yields favorable prognosis, while cases with c-Kit mutation are classified as intermediate-risk. The conventional '3+7' chemotherapy regimen demonstrates high response rates. | ||||